Novocure stock surged after the Food and Drug Administration approved its Optune Pax product, which delivers tumor treating ...

AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI ...

With this in mind, let's check out a blastoff-ready biotech stock you'll kick yourself for not buying in 2026. Image source: Getty Images.

IO Biotech, Inc. (IOBT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value ...

Krystal Biotech received FDA RMAT designation for inhaled KB707 in advanced NSCLC, based on a 36% ORR in heavily pretreated ...

Biotech stocks are gaining momentum as weight-loss drugs, pipeline depth and clinical data drive renewed growth optimism.

A sales partner offered a ray of hope that this company couldn't for itself.

Investing.com -- Jefferies upgraded Medpace to Buy, saying a rebound in biotech funding, a conservative balance sheet and reduced near-term risk from artificial intelligence set up the stock for a ...

Michael Yee, global head of biotech research at UBS, joins CNBC’s ‘Squawk on the Street’ to explain Moderna's narrower-than-expected loss, why healthcare is outperforming, and vaccine mandates and ...

Moderna Inc (NASDAQ:MRNA) has delivered a 37% gain year-to-date, dramatically outpacing the biotech sector’s 0.4% YTD return.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best upside stocks to invest in right now. On January 30, Bank of America lowered its price target on Alnylam to $462 from $529 while ...